Five-Year Follow-Up of the Phase III ASCOT Trial of Adjuvant S-1 After Resection for Biliary Tract Cancer
Source: View publication →
The 5-year final analysis of the phase III ASCOT trial confirms that adjuvant S-1 significantly and sustainably improves overall and relapse-free survival compared to observation in patients with curatively resected biliary tract cancer.
Key Findings
Study Design
Study Limitations
Clinical Significance
This mature 5-year analysis provides definitive, Level I evidence that adjuvant S-1 confers a substantial and lasting overall survival benefit in resected biliary tract cancer. By increasing 5-year OS from 52% to 64% and extending median OS from 5.9 to 8.2 years, the ASCOT trial establishes adjuvant S-1 as a highly effective standard-of-care regimen for this disease, particularly in Asian populations. These data cement the role of fluoropyrimidine-based adjuvant therapy in curative-intent treatment paradigms for biliary tract cancer.
Historical Context
Historically, biliary tract cancer (BTC) has been associated with poor outcomes and high recurrence rates following surgical resection. For many years, the role of adjuvant therapy was controversial due to a lack of statistically significant, large-scale, prospective randomized data. The Western standard shifted in 2019 following the BILCAP trial, which positioned capecitabine as the standard of care despite its primary intention-to-treat analysis narrowly missing statistical significance for overall survival. In Asia, the initial report of the ASCOT trial demonstrated a clear 3-year OS benefit for S-1 (a combination of tegafur, gimeracil, and oteracil). This 2026 final 5-year update provides highly rigorous, mature confirmation of that benefit, definitively resolving questions about the long-term efficacy of adjuvant systemic therapy in this setting.
Guided Discussion
High-yield insights from every perspective
S-1 is the oral fluoropyrimidine combination used in the ASCOT trial. What are the three distinct pharmacological components of S-1, and what is the specific mechanistic rationale for combining them rather than administering 5-fluorouracil (5-FU) alone?
Key Response
S-1 consists of tegafur (a prodrug of 5-FU), gimeracil (a potent reversible inhibitor of dihydropyrimidine dehydrogenase [DPD] that prevents 5-FU degradation), and oteracil (which inhibits the phosphorylation of 5-FU specifically in the gastrointestinal tract). This question tests foundational pharmacology, highlighting how drug design can maintain systemic drug levels while minimizing localized GI toxicity like severe diarrhea.
A patient with newly curatively resected extrahepatic cholangiocarcinoma is referred for adjuvant therapy. Based on the 5-year ASCOT data and the earlier BILCAP trial, how do you discuss the choice between S-1 and capecitabine, and what distinct toxicity profiles should the patient anticipate?
Key Response
Residents must translate trial data into clinical counseling. While ASCOT establishes S-1 as highly effective with an OS benefit, BILCAP established capecitabine as the standard in many Western countries. The resident must know to counsel on hand-foot syndrome (more prominent with capecitabine) versus hematologic toxicities and gastrointestinal side effects (associated with S-1).
Biliary tract cancer encompasses intrahepatic, extrahepatic, gallbladder, and ampullary carcinomas. How should the anatomical site of the primary tumor influence your interpretation of the ASCOT trial's 5-year efficacy data, and is the adjuvant benefit of S-1 uniform across these distinct disease entities?
Key Response
Fellows need to recognize the profound biological heterogeneity of biliary tract cancers. Subgroup analyses in large trials often show differential benefits; for example, gallbladder cancer historically responds differently than intrahepatic cholangiocarcinoma. Interpreting the forest plots of the ASCOT 5-year update is critical to determine if the overall survival benefit is broadly applicable or driven predominantly by a specific anatomical cohort.
Given the sustained 5-year overall survival benefit of S-1 in the ASCOT trial, which was conducted primarily in Asian populations, how should Western oncologists integrate these findings into practice considering the known pharmacogenomic differences in fluoropyrimidine metabolism?
Key Response
Attendings must consider the global applicability of trial results. Western populations often have different polymorphisms in CYP2A6 and DPD compared to Asian populations, leading to drastically different tolerability profiles for S-1 (often requiring lower doses and causing more GI toxicity in Western patients). This challenges the direct translation of the ASCOT survival curves to non-Asian clinical practices without careful dose modification.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The ASCOT trial utilized observation as the control arm. From a methodological and statistical standpoint, how does the rapidly evolving landscape of post-recurrence targeted therapies (e.g., FGFR and IDH1 inhibitors) confound the interpretation of the 5-year overall survival endpoint, and how should this be controlled for in the final analysis?
Key Response
Researchers must evaluate how subsequent lines of therapy influence long-term overall survival. If patients in the observation arm recurred but subsequently had access to novel, highly effective targeted therapies that were unavailable at the trial's initiation, OS curves could narrow. Methodologists must scrutinize the collection of and statistical adjustment for post-progression treatments to validate the true OS effect size of the adjuvant S-1 intervention.
As a peer reviewer assessing this 5-year follow-up manuscript, what specific statistical data regarding the proportional hazards assumption and informative censoring would you demand to see to ensure the reported long-term survival benefit is robust and not an artifact of trial attrition?
Key Response
Editors must rigorously assess late-curve stability. A tough reviewer would flag whether the hazards remained proportional over the full 5 years, demand a competing risks analysis for non-cancer-related mortality, and strictly scrutinize the drop-out and censoring patterns between the S-1 and observation arms at the tail end of the Kaplan-Meier curves to ensure the reported benefit is mathematically sound.
Current ASCO and NCCN guidelines recommend adjuvant capecitabine for resected biliary tract cancer based on the BILCAP trial, which notably missed its primary ITT overall survival endpoint but was adopted based on sensitivity analysis. With ASCOT showing a definitive 5-year OS benefit, how should guideline committees grade the evidence for S-1 versus capecitabine, and should regional guidelines explicitly diverge?
Key Response
Guideline committees must compare the statistical robustness of foundational trials. ASCOT provides arguably stronger Level I statistical evidence for an OS benefit than BILCAP's primary analysis. Committees (like ESMO or NCCN) would likely grant S-1 a strong recommendation (Category 1) for Asian populations, while debating its role as an alternative option in Western guidelines due to population-based tolerability issues, highlighting the need for geographically tailored clinical practice guidelines.
Clinical Landscape
Noteworthy Related Trials
BCAT Trial
Tested
Adjuvant gemcitabine
Population
Patients with resected extrahepatic cholangiocarcinoma
Comparator
Observation
Endpoint
Overall survival
BILCAP Trial
Tested
Adjuvant capecitabine
Population
Patients with completely resected biliary tract cancer
Comparator
Observation
Endpoint
Overall survival
PRODIGE 12-ACCORD 18 Trial
Tested
Adjuvant gemcitabine plus oxaliplatin (GEMOX)
Population
Patients with resected biliary tract cancer
Comparator
Observation
Endpoint
Relapse-free survival
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis